Palmer Square Capital BDC Bolsa (NYSE: PSBD)

Últimas noticias sobre Palmer Square Capital BDC (NYSE:PSBD) Bolsa

Palmer Square Capital BDC

Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.

Palmer Square Capital BDC Inc. Common Stock

Palmer Square Capital BDC Inc

Gold Royalty has achieved record revenue, and Total Revenue, Land Agreement Proceeds and Interest&#x2A; for both the second quarter and first half of 2025. Total Revenue, Land Agreement Proceeds and Interest&#x2A; in the second quarter of 2025 increased by approximately 100% to $4.4 million (revenue of $3.8 million) from the second quarter of 2024, equating to 1,346 gold equivalent ounces ("GEOs")&#x2A;. For the first half of 2025, Total Revenue, Land Agreement and Proceeds and Interest also increased by 25% from the same period in 2024 to a record $8.0 million (revenue of $6.9 million), equating to 2,595 GEOs.
Further growth in revenue is currently expected through 2025, driven by strong commodity prices supporting the Company's cash flowing royalties at Canadian Malartic, Côté, Borborema, Cozamin and Borden (Porcupine) and the Vareš&nbsp;copper stream.Gold Royalty maintains its 2025 full-year production guidance 5,700 - 7,000 GEOs as released on March 20, 2025, and expects that production will be more heavily weighted to the second half of the year as recently-started mining operations including Côté, Vareš, and Borborema continue to ramp up towards full production run rates through 2025.
&#x2A; Total Revenue, Land Agreement Proceeds and Interest and GEOs are each non-IFRS financial measures. See "Non-IFRS Measures" below.

News

General

GROY

Gold Royalty Corp Announces  Its Preliminary Results For Q2 2025; Total Revenue, Land Agreement Proceeds And Interest In Q2 2025 Increased By ~100% To $4.4M

Heritage Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.19 by 47.37 percent. This is a 33.33 percent decrease over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $47.782 million which beat the analyst consensus estimate of $45.282 million by 5.52 percent. This is a 14.50 percent increase over sales of $41.731 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

HTBK

Heritage Commerce Q2 EPS $0.10 Misses $0.19 Estimate, Sales $47.782M Beat $45.282M Estimate

Management

Heritage Commerce And Heritage Bank Of Commerce Appoints Seth Fonti As CFO

Ovintiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $0.97 by 21.9 percent. This is a 4.07 percent decrease over earnings of $1.23 per share from the same period last year.

Ovintiv Q2 Adj. EPS $1.18 Beats $0.97 Estimate

UNIT

Uniti Group And New Windstream Receive Necessary Regulatory Approvals To Complete Merger

All financial figures are in Canadian dollars unless otherwise noted.
Pembina Pipeline Corporation ("Pembina") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PPL#TSX">PPL</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBA#NYSE">PBA</a>) announced today that Alliance Pipeline Limited Partnership ("Alliance") has reached a negotiated settlement (the "Settlement") with shippers and interested parties (the "Shipper Committee") on the Canadian portion of the Alliance Pipeline and filed an application with the Canada Energy Regulator (the "CER") seeking approval of the Settlement. Separately, Alliance announced it is soliciting non-binding expressions of interest for a new regional short-haul transportation service.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20250724759654/en/">https://www.businesswire.com/news/home/20250724759654/en/</a>
"We are pleased after many months of complex, yet productive, discussions to have reached a negotiated solution with the Shipper Committee, consisting of over 30 members," said Scott Burrows, Pembina's President and Chief Executive Officer. "The negotiated tolls are competitive and will provide toll certainty to Shippers. The Settlement is fair and equitable to Alliance and all Shippers. We now look forward to a timely response from the CER."
In November 2024, the CER ordered Alliance to submit for approval a detailed toll application justifying why its current tolling methodology remained compliant with the Canadian Energy Regulator Act, or a new tolling methodology application. Likewise, the CER ordered that the current tolls be deemed interim tolls until resolution of the above. Following the CER order, Alliance worked collaboratively with the Shipper Committee towards a negotiated settlement.
Highlights of the Settlement include:
<ul>
<li>A 10-year term, effective November 1, 2025 - October 31, 2035.</li>
<li>A revised term-differentiated toll schedule that includes the establishment of a new 10-year toll and a reduction to the existing 1-year, 3-year and 5-year tolls ("New Tolls"). The New Tolls are expected to reduce existing long-term firm tolls by an average of 14 percent on a volume weighted average basis.</li>
<li>All existing long-term firm service contracts will incorporate the New Tolls, and the New Tolls will remain fixed for the 10-year period effective November 1, 2025.</li>
<li>The Settlement offers existing long-term firm shippers a one-time term extension option, enabling shippers to take advantage of the new term-differentiated tolls, effective November 1, 2025. Alliance anticipates a significant portion of contracted volumes to take advantage of the 10-year toll, thereby extending the weighted average term of Alliance's contractual profile.</li>
<li>Revenue from biddable transportation service (seasonal and interruptible) for volumes above long-term firm capacity of 1.325 billion cubic feet per day, will be shared 50/50 between Alliance and firm and seasonal shippers, thus aligning the interests of Alliance and its shippers and maintaining Alliance's ability to fairly and equitably allocate short-term capacity when available and demanded by the market.</li>
<li>The Settlement has no retroactive impact on the interim tolls in effect since November 2024. The interim tolls will be made final and apply until October 31, 2025.</li>
<li>Alliance will remain under an 'at-risk' commercial model where returns and Alliance's ability to recover operating costs are squarely driven by the customer demand for its service and Alliance's ability to efficiently provide such service and manage costs.</li>
<li>Alliance will return approximately $95 million, currently held as an existing liability on Alliance's balance sheet, associated with eligible recoverable costs ("Recoverable Cost Variance"). The economic impact to Alliance of the return of this balance is limited to foregone carrying charges, which previously accrued at 8.75 percent. Alliance's ability to recover the same limited categories of cost in the future via surcharges under the Settlement is unchanged.</li>
</ul>
The Shipper Committee supported the Settlement through a vote on July 23, 2025. The Settlement is contingent on approval by the CER. Alliance has filed an application with the CER requesting approval of the Settlement by September 15, 2025. The full application is available for viewing on the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fapps.cer-rec.gc.ca%2FREGDOCS%2FItem%2FFiling%2FC35716&amp;esheet=54296397&amp;newsitemid=20250724759654&amp;lan=en-US&amp;anchor=CER+Website&amp;index=1&amp;md5=20a6dbf4b64d11b8367c708a4865736b">CER Website</a>.
Pembina expects the financial impact to Alliance from the Settlement over the next 10 years will be an approximately $50 million per year reduction in long-term firm service revenue, plus the impact of the new revenue sharing provision. The impact of the revenue sharing provision is subject to biddable transportation service tolls, which will depend primarily on future commodity prices. The estimated impact of the revenue sharing provision assuming an AECO-Chicago natural gas spread of C$1.50 per thousand cubic feet ("mcf") is approximately $40 million. The estimated impact of every incremental C$0.25/mcf change is approximately $10 million. Applying the terms of the Settlement to Alliance's financial results over the historical five-year period from 2020 to 2024, the average annual impact of the Settlement, including the reduction in long-term firm service revenue and the impact of the new revenue sharing provision, would have been approximately $95 million.
Alliance has a proven track record of high reliability and high utilization and is unique in its ability to transport liquids-rich, Canadian-produced natural gas, while providing a cross-border conduit to high demand U.S. markets. Pembina looks forward to continuing to deliver exceptional customer service and maximizing the value of this critical and highly differentiated North American energy infrastructure asset.

Legal

TSX:PPL

Pembina's Alliance Pipeline Reaches 10-Year Toll Settlement With Shippers, Cutting Long-Term Firm Tolls By 14% And Returning $95M In Liabilities; Canada Energy Regulator Approval Sought By Sept. 15

Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2025, to be held October 17-21 in Berlin.
"We're looking forward to presenting the latest findings across our oncology portfolio at this year's congress, including initial data for our TGFβR2×PD-1-directed bispecific antibody, INCA33890, and our novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, INCB161734," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "These data underscore the importance of establishing treatment options for advanced solid tumors and speak to the potential of INCA33890 and INCB161734 as personalized therapies to enhance outcomes for patients with cancer across a range of tumor types."

Biotech

INCY

Incyte To Present Key Data From Its Oncology Portfolio At The Upcoming European Society Of Medical Oncology Congress 2025, To Be Held October 17-21 In Berlin; Mini Oral Presentation To Highlight Initial Phase 1 Data Of INCA33890; Oral Presentation To Feature Initial Data Of INC161734

<h3>Gainers</h3>
<ul>
<li>Coursera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) shares increased by 22.0% to $11.08 during Thursday's after-market session. The market value of their outstanding shares is at $1.4 billion. The company's, Q2 earnings came out today. </li>
<li>CarParts.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTS#NASDAQ">PRTS</a>) shares increased by 7.34% to $0.87. The market value of their outstanding shares is at $51.2 million. </li>
<li>Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) stock increased by 6.73% to $112.01. The company's market cap stands at $16.1 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Flexsteel Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXS#NASDAQ">FLXS</a>) stock moved upwards by 5.52% to $38.23. The company's market cap stands at $203.2 million. </li>
<li>Yatra Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTRA#NASDAQ">YTRA</a>) stock increased by 4.77% to $0.94. The market value of their outstanding shares is at $55.2 million. </li>
<li>Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) stock moved upwards by 4.69% to $1.56. The market value of their outstanding shares is at $169.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>U Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) shares fell 8.9% to $2.67 during Thursday's after-market session. The company's market cap stands at $16.8 million. </li>
<li>Aureus Greenway Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) stock fell 6.53% to $1.72. The company's market cap stands at $26.5 million. </li>
<li>REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) stock declined by 5.17% to $0.71. The company's market cap stands at $21.6 million. </li>
<li>Smart Share Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) stock declined by 4.35% to $1.1. The market value of their outstanding shares is at $289.0 million. </li>
<li>E-Home Household Service (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) stock decreased by 4.33% to $1.66. </li>
<li>ADT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) shares declined by 4.27% to $8.3. The market value of their outstanding shares is at $7.0 billion. The company's, Q2 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CHGG

COUR

DECK

FLXS

PRTS

UCAR

YTRA

12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) stock rose 55.0% to $7.95 during Thursday's after-market session. The company's market cap stands at $12.1 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) shares increased by 10.55% to $31.42. The company's market cap stands at $341.7 million. </li>
<li>X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) shares moved upwards by 10.38% to $2.02. The company's market cap stands at $10.7 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares increased by 8.69% to $5.58. The company's market cap stands at $4.2 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock increased by 8.67% to $1.44. The company's market cap stands at $23.5 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock rose 7.47% to $3.84. The market value of their outstanding shares is at $6.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock declined by 16.2% to $0.05 during Thursday's after-market session. The market value of their outstanding shares is at $10.2 million. </li>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) stock declined by 14.58% to $0.77. The market value of their outstanding shares is at $44.7 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 12.58% to $0.12. The market value of their outstanding shares is at $1.5 million. </li>
<li>Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) shares decreased by 11.12% to $3.12. The market value of their outstanding shares is at $449.0 million. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares declined by 8.34% to $11.0. The company's market cap stands at $43.2 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock decreased by 8.31% to $9.16. The company's market cap stands at $5.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABSI

COEP

HCTI

IRIX

NMTC

NXTC

PTHL

SNOA

TNFA

TTNP

XFOR

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) shares rose 18.6% to $0.68 during Thursday's after-market session. The company's market cap stands at $92.7 million. </li>
<li>Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) shares moved upwards by 13.26% to $637.5. The market value of their outstanding shares is at $19.3 billion. The company's, Q2 earnings came out today. </li>
<li>Resources Connection (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGP#NASDAQ">RGP</a>) stock increased by 8.12% to $5.7. The market value of their outstanding shares is at $182.0 million. As per the news, the Q4 earnings report came out today. </li>
<li>Huachen AI Parking Mgmt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAI#NASDAQ">HCAI</a>) stock rose 7.15% to $0.9. The company's market cap stands at $31.0 million. </li>
<li>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) shares increased by 6.22% to $2.9. The market value of their outstanding shares is at $57.7 million. </li>
<li>FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) shares rose 4.75% to $0.78. The market value of their outstanding shares is at $125.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) stock decreased by 49.7% to $0.15 during Thursday's after-market session. The company's market cap stands at $3.1 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares declined by 9.94% to $0.08. The market value of their outstanding shares is at $4.1 million. </li>
<li>Proficient Auto Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAL#NASDAQ">PAL</a>) stock decreased by 7.9% to $7.46. The company's market cap stands at $224.6 million. </li>
<li>Silynxcom (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#AMEX">SYNX</a>) shares decreased by 7.33% to $1.77. The market value of their outstanding shares is at $12.8 million. </li>
<li>FBS Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBGL#NASDAQ">FBGL</a>) stock fell 6.53% to $0.65. The company's market cap stands at $8.3 million. </li>
<li>Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) shares declined by 6.35% to $4.43. The company's market cap stands at $5.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FBGL

HCAI

HTOO

LNZA

NOTE

SYNX

WLGS

12 Industrials Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) shares increased by 28.1% to $0.27 during Thursday's after-market session. The company's market cap stands at $10.2 million. </li>
<li>Saiheat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIH#NASDAQ">SAIH</a>) shares rose 8.26% to $12.99. The market value of their outstanding shares is at $16.4 million. </li>
<li>Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) shares increased by 6.7% to $109.88. The company's market cap stands at $1.3 billion. As per the news, the Q2 earnings report came out today. </li>
<li>Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) shares moved upwards by 5.73% to $0.8. The market value of their outstanding shares is at $15.3 million. </li>
<li>Infobird Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) stock moved upwards by 5.6% to $1.13. The market value of their outstanding shares is at $8.7 million. </li>
<li>AuthID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) shares increased by 4.83% to $4.12. The company's market cap stands at $56.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mercurity Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) stock declined by 19.2% to $2.48 during Thursday's after-market session. The market value of their outstanding shares is at $127.6 million. </li>
<li>Youxin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YAAS#NASDAQ">YAAS</a>) shares declined by 14.33% to $0.5. The company's market cap stands at $14.0 million. </li>
<li>Data I/O (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAIO#NASDAQ">DAIO</a>) shares decreased by 6.71% to $3.2. The market value of their outstanding shares is at $29.9 million. The company's, Q2 earnings came out today. </li>
<li>GSI Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIT#NASDAQ">GSIT</a>) shares declined by 6.18% to $4.56. The market value of their outstanding shares is at $149.8 million. </li>
<li>T Stamp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) shares decreased by 4.93% to $2.7. The company's market cap stands at $7.1 million. </li>
<li>Pixelworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) stock decreased by 4.35% to $13.0. The market value of their outstanding shares is at $66.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AUID

BELFB

DAIO

GSIT

IDAI

IFBD

PXLW

SAIH

SMSI

YAAS

12 Information Technology Stocks Moving In Thursday's After-Market Session

– Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo –
– CABOMETYX is the first and only systemic therapy to be approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy –
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54296414&amp;newsitemid=20250724850513&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=e8f7628f70d3d2f87fd276766415d0d6">Exelixis, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX&#xAE; (cabozantinib) for the treatment of adult patients with unresectable or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This approval follows the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.exelixis.com%2Fnews-releases%2Fnews-release-details%2Fexelixis-partner-ipsen-receives-positive-chmp-opinion-1&amp;esheet=54296414&amp;newsitemid=20250724850513&amp;lan=en-US&amp;anchor=positive+opinion&amp;index=2&amp;md5=3c21cff5aa706ddbcc6cc5c65ddaa869">positive opinion</a> received from the European Medicines Agency's Committee for Medicinal Products for Human Use in June 2025 and allows for the marketing of CABOMETYX in this indication in all 27 member states of the European Union (EU), Norway, Liechtenstein and Iceland.

Global

EXEL

Exelixis Announces EU Approval Of CABOMETYX As First Systemic Therapy For Previously Treated Neuroendocrine Tumors

AST SpaceMobile Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares are tumbling in Thursday&#8217;s after-hours session after the company announced a <a href="https://www.benzinga.com/pressreleases/25/07/b46616411/ast-spacemobile-announces-proposed-private-offering-of-500-0-million-of-convertible-senior-notes-d">proposed private offering</a>.
Check out the current price of <a href="https://www.benzinga.com/quote/ASTS">ASTS stock here.</a>
What Happened: AST SpaceMobile said it intends to offer $500 million of convertible senior notes due 2032 in a private offering to institutional investors. The company plans to grant the initial purchasers a 13-day option to purchase up to an additional $75 million of the notes. 
AST SpaceMobile intends to use the net proceeds to pay the cost of the capped call transactions in connection with the offering, as well as for general corporate purposes.
AST SpaceMobile also <a href="https://www.benzinga.com/pressreleases/25/07/b46616405/ast-spacemobile-announces-proposed-repurchase-of-up-to-135-0-million-convertible-senior-notes-to-b">announced</a> a concurrent cash repurchase of up to $135 million worth of its&nbsp;4.25%&nbsp;convertible senior notes due 2032. Last month, the company announced a $225 million repurchase of the same notes in privately negotiated repurchase transactions with a limited number of holders.
AST SpaceMobile had a total of $874.5 million in cash, cash equivalents and restricted cash as of March 31. The company is due to report second-quarter financial results next month, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
<h2 class="wp-block-heading">How To Buy ASTS Stock</h2>
By now, you're likely curious about how to participate in the market for AST SpaceMobile — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option or sell a call option at a strike price above where shares are currently trading — either way, it allows you to profit from the share price decline.
ASTS Price Action: <a href="http://benzinga.com/quote/ASTS">AST SpaceMobile shares</a> were down 9.44% in after-hours, trading at $54.39 at the time of publication on Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/space/25/07/46534529/space-stock-tracker-virgin-galactic-makes-a-comeback-while-rocket-lab-takes-a-breather">Space Stock Tracker: Virgin Galactic Makes A Comeback While Rocket Lab Takes A Breather</a></li>
</ul>
Photo: hakanyalicn/Shutterstock.com

SPACE

Offerings

After-Hours Center

ASTS

AST SpaceMobile Stock Is Tumbling After The Bell: Here's Why

As global energy demand rises, companies like GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) are strategically positioning themselves to capitalize on the shift towards electrification and renewable power. This broader trend is reflected in the company&#8217;s latest financial performance, promising <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46575967/ge-vernova-posts-better-than-expected-earnings-joins-thermo-fisher-scientific-lennox-international-general-dynamics-and-other-big-stocks-moving-higher-on-wednesday">significant growth opportunities.</a>
<ul class="wp-block-list">
<li>GEV is showing strength near its 52-week high. <a href="https://www.benzinga.com/quote/GEV" target="_blank" rel="noreferrer noopener">See the chart here.</a></li>
</ul>
GE Vernova reported better-than-expected earnings for the second quarter on Wednesday. The announcement came amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. 
Here are some key analyst takeaways.
RBC Capital Markets On GE Vernova
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6356909f2cec4c00018e29ef/chris-dendrinos">Analyst Christopher Dendrinos</a> maintained an Outperform rating, while raising the price target from $561 to $631.
GE Vernova reported total revenues of $9.1 billion, up 11% year-on-year and higher than consensus of $8.8 billion, Dendrinos said in a note. The company's total orders grew around 4% year-on-year to $12.4 billion, "driven by continued strong demand in Power and Electrification," he added.
GE Vernova strong sales and orders are "continued proof points that there is additional positive momentum in the long-term margin opportunity," the analyst wrote. The company seems poised to reach its 2028 margin target as early as in 2026, he further wrote.
&nbsp;Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
BMO Capital Markets On GE Vernova
Analyst Ameet Thakkar reiterated an Outperform rating, while lifting the price target from $590 to $690.
The rally in GE Vernova's stock following the earnings release had less to do with the second-quarter beat and full-year guidance increase, Thakkar said. The stock was driven by "signals of power market tightening," he wrote.
The company had projected to reach 14% EBITDA margins by 2028, based on its Power and Electrification segments reaching 16% margins, the analyst stated. While the Power segment already reached 16.4% EBITDA margins in the second quarter, the Electrification business is likely to cross 16% in the fourth quarter, he added.
GEV Price Action: GE Vernova shares were up 0.36% at $631.27 at the time of publication on Thursday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro.</a>
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46111337/micron-ceo-cautions-ai-boom-may-not-be-fully-sustainable-flags-tariff-driven-demand-pull-in"> Trump&#8217;s Sledgehammer Policies Have Ignited Wall Street&#8217;s Hottest Trade—And It&#8217;s Not AI</a></li>
</ul>
Photo: Shutterstock

Reiteration

Analyst Ratings

GE Vernova's Q2 Beat May Push 2028 Profit Margin Target 2 Years Early

Minerals Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTX#NYSE">MTX</a>) reported quarterly earnings of $1.55 per share which beat the analyst consensus estimate of $1.41 by 10.16 percent. This is a 6.06 percent decrease over earnings of $1.65 per share from the same period last year. The company reported quarterly sales of $528.900 million which missed the analyst consensus estimate of $529.133 million by 0.04 percent. This is a 2.27 percent decrease over sales of $541.200 million the same period last year.

Minerals Technologies Q2 Adj. EPS $1.55 Beats $1.41 Estimate, Sales $528.900M Miss $529.133M Estimate

VeriSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>) raises FY2025 sales outlook from $1.635 billion-$1.650 billion to $1.645 billion-$1.655 billion vs $1.643 billion estimate.

Guidance

VRSN

VeriSign Raises FY2025 Sales Guidance from $1.635B-$1.650B to $1.645B-$1.655B vs $1.643B Est

Primis Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRST#NASDAQ">FRST</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.21 by 47.12 percent. This is a 65.63 percent decrease over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $43.518 million which beat the analyst consensus estimate of $28.134 million by 54.68 percent. This is a 3.33 percent increase over sales of $42.116 million the same period last year.

FRST

Primis Finl Q2 Adj. EPS $0.11 Misses $0.21 Estimate, Sales $43.518M Beat $28.134M Estimate

WIIM

PNFP

SVNBY

Synovus Financial and Pinnacle Financial Partners shares are trading lower after announcing an all-stock merger.

7 analysts have shared their evaluations of CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $296.57, a high estimate of $305.00, and a low estimate of $275.00. This upward trend is apparent, with the current average reflecting a 2.93% increase from the previous average price target of $288.14.
<img src="https://www.benzinga.com/files/images/story/2025/1753390834_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of CME Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$305.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$303.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$298.00</td>
<td>$299.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$296.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$299.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$275.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$282.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CME Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CME Group compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of CME Group's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CME Group's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CME/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CME Group analyst ratings.</a>
<h2>Unveiling the Story Behind CME Group</h2>
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&amp;P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&amp;P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
<h3>CME Group's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining CME Group's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.38% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 57.49%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): CME Group's ROE excels beyond industry benchmarks, reaching 3.53%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.64%, the company showcases effective utilization of assets.
Debt Management: CME Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.13.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down CME Group: 7 Analysts Share Their Views

Looking into the current session, Ingersoll Rand Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) shares are trading at $86.89, after a 0.07% increase. Moreover, over the past month, the stock went up by 2.30%, but in the past year, fell by 11.97%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1753390824_0.png" alt="Past Year Chart" />

<h3>Comparing Ingersoll Rand P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 28.28 in the Machinery industry, Ingersoll Rand Inc. has a higher P/E ratio of 42.99. Shareholders might be inclined to think that Ingersoll Rand Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1753390824_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into Ingersoll Rand Inc's Price Over Earnings

Press Releases

Palmer Square Capital BDC Announces Fourth Quarter 2024 Supplemental Dividend of $0.06

Fintech

Palmer Square Capital Management Set to Launch First European CLO ETFs

Palmer Square Capital BDC Announces Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

Palmer Square Capital BDC Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

Palmer Square Capital BDC Inc. Announces First Quarter 2025 Supplemental Dividend of $0.03

Palmer Square Capital BDC Inc. Announces First Quarter 2025 Earnings Release and Conference Call

Palmer Square Capital BDC Inc. Announces First Quarter 2025 Financial Results

Palmer Square's CLO Indices Celebrate 10 Year Anniversary

Palmer Square Capital BDC Announces Second Quarter 2025 Supplemental Dividend of $0.06

Palmer Square Capital BDC Inc. Announces Second Quarter 2025 Earnings Release and Conference Call

Comments

Palmer Square Capital BDC

Noticias

Últimas noticias sobre Palmer Square Capital BDC (NYSE:PSBD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL